Preferred Label : Tigilanol Tiglate;
NCIt definition : A short-chain diterpene ester isolated from the seed of Fontainea picrosperma, with
potential antineoplastic activity. Upon intratumoral administration, tigilanol tiglate
disrupts mitochondrial functioning and induces mitochondrial swelling, which leads
to oncolysis of tumor cells that are in direct contact of the agent. In addition,
tigilanol tiglate activates protein kinase C (PKC) signaling cascade, which leads
to an acute inflammatory response. This results in hypoxia and activates innate immune
cells including neutrophils and macrophages, thereby further killing tumor cells.
The activation of the beta-II isoform of PKC (PKC beta II ) also increases tumor vasculature
permeability, which leads to the destruction of tumor vasculature.;
UNII : R1ZJT87990;
InChIKey : YLQZMOUMDYVSQR-FOWZUWBHSA-N;
CAS number : 943001-56-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 943001-56-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : EBC-46; EBI-46;
NCI Metathesaurus CUI : CL553826;
Origin ID : C152622;
UMLS CUI : C4726858;
- Semantic type(s)
- concept_is_in_subset
- has_target
https://ansm.sante.fr/tableau-acces-derogatoire/tigilanol-tiglate
2024
false
false
false
France
French
Tigilanol Tiglate
drug information
Intratumoral use
---